Immunovant, Inc. (IMVT) shares climbed 7.5% to $30.53 as of November 7, 2026, a significant gain from the prior close of $28.39. BestStocks flagged the session as a major change for IMVT. The move is tied to price move up. Below, we break down what changed for IMVT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
IMVT climbed 7.5% to $30.53
IMVT climbed 7.5% in its latest session, moving from $28.39 to $30.53.
Material / EarningsMedium confidence
Rel. volume
2.1×
Very High
Vs peers
—
No comparable peers
Market cap
$6.3B
NASDAQ Global Select
Analyst target
$40
+31.0% vs price
Price chart
Oct 7 – Nov 6
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Immunovant, Inc. investors
For Immunovant, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 7.5% price move with conviction. Weighing against that: Immunovant halted development of IMVT-1402 in cutaneous lupus erythematosus after its proof-of-concept trial missed its primary endpoint, per Yahoo Finance reporting; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $40.00, implying +31.0% upside from $30.53. BestStocks rates the overall signal quality medium (67/100). With earnings roughly 2 days out, the next report is the most likely near-term test of the move.
IMVT price reaction
IMVT last traded at $30.53, up $2.14 (+7.54%) from the previous close of $28.39. The session traded on 2.1× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $26.73 and $32.04, and it currently sits about 72% of the way up that band.
Bullish and bearish analyst opinions on Immunovant, Inc. (IMVT)
The consensus analyst price target on Immunovant, Inc. (IMVT) is $40.00, 31.0% above the recent $30.53. Here is how the bullish and bearish cases on IMVT line up.
▲ The bullish case
+Wall Street's consensus price target of $40.00 implies +31.0% upside from $30.53.
+The Street's most bullish target is $40.00 (+31.0%).
+Material positive event.
+Strong 7.5% price move with conviction.
+Volume 2.1x average — institutional conviction.
▼ The bearish case
−Immunovant halted development of IMVT-1402 in cutaneous lupus erythematosus after its proof-of-concept trial missed its primary endpoint, per Yahoo Finance reporting.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 7, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Immunovant, Inc. (IMVT) moved -3.73% from $29.49 to $28.39 on 2026-11-05. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Material / Earnings2026-11-02-2.6%
Immunovant, Inc. (IMVT) moved -3.10% from $29.32 to $28.41 on November 2, 2026. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating the move occurred without unusual trading activity.
Material / Earnings2026-10-28+1.9%
Immunovant, Inc. (IMVT) moved +3.23% from $28.50 to $29.42 on 2026-10-28. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move lacked unusual momentum.
Material / Earnings2026-10-27+2.5%
Immunovant, Inc. (IMVT) moved +2.92% from $28.06 to $28.88 on 2026-10-27. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting routine trading.
Material / Earnings2026-10-22+2.5%
Immunovant, Inc. (IMVT) moved +3.60% from $28.09 to $29.10 on October 22, 2026. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move occurred on below-average volume (0.8x the 5-day average).
News2026-10-21-0.7%
Immunovant will report Q2 FY2026 financial results and business update on November 9, 2026.
Material / Earnings2026-10-20+3.5%
Immunovant, Inc. (IMVT) moved +2.99% from $27.76 to $28.59 on 2026-10-20. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, indicating typical trading activity.
Immunovant halted development of IMVT-1402 in cutaneous lupus erythematosus after its proof-of-concept trial missed its primary endpoint, per Yahoo Finance reporting. The halt has triggered a 4.17% intraday decline to $29.20, compounded by sector-wide pressure following Argenx's Sjögren's trial failure in the same drug class. Volume remains below average at 0.43x expected for this time of session.
Upcoming catalysts & outlook
Next earnings
2026-11-09 (est.)
in 2 days
Thesis shift
Bullish Shift
bullish signal
Risk level
Medium
from change events
Frequently asked questions about IMVT
Why did Immunovant, Inc. (IMVT) stock move?
IMVT climbed 7.5% to $30.53. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IMVT stock rise?
IMVT gained 7.54% ($2.14) versus the prior close of $28.39, last trading at $30.53 on 2.1× average volume.
When is Immunovant, Inc.'s next earnings date?
IMVT's next earnings report is estimated for 2026-11-09 — about 2 days away.
What is the analyst price target for IMVT?
The consensus analyst price target for IMVT is $40.00, about 31.0% above the current $30.53. Over the past 90 days, analysts recorded 0 upgrades, 0 maintains, and 0 downgrades.
How BestStocks tracks IMVT
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for IMVT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 7, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
